RI-MUHC Annual Report

YEAR IN REVIEW

INFECTIOUS DISEASES AND IMMUNITY IN GLOBAL HEALTH (IDIGH) PROGRAM

RESEARCH HIGHLIGHTS

First large-scale efficacy studies of a plant-derived influenza vaccine

Dr. Brian Ward and colleagues showed in two multicentre phase 3 efficacy studies that a recombinant quadrivalent virus-like particle (QVLP) influenza vaccine, manufactured in plants by Medicago, is safe and protective against influenza. QVLP vaccines might address some of the limitations of current vaccines. Published in The Lancet.

Repurposing facilities to advance COVID-19 research

WIth a seed grant from the MUHC Foundation and partners, Dr. Marcel Behr and his team repurposed existing Containment Level 3 facilities at the RI-MUHC and McGill University to conduct live SARS-Cov-2 research. This research has accelerated with funding from the Canada Foundation for Innovation.

Dr. Brian Ward, Fiona Mcintosh, Containment Level 3 platform manager, and Dr. Marcel Behr
Dr. Brian Ward, Fiona Mcintosh, Containment Level 3 platform manager, and Dr. Marcel Behr

Study of hydroxychloroquine usage may help personalize lupus treatment

Dr. Sasha Bernatsky and postdoctoral fellow Celline Brasil, PhD, identified predictors of unsuccessful hydroxychloroquine tapering and discontinuation in lupus patients. This understanding of outcomes is a first step toward personalized treatment. Published in Journal of Arthritis Care and Research.

Dr. Sasha Bernatsky and postdoctoral fellow/first study author Celline Brasil, PhD
Dr. Sasha Bernatsky and postdoctoral fellow/first study author Celline Brasil, PhD

Selected news links

rimuhc.ca/IDIGH